Corona Remedies IPO GMP at ₹365 (34% Surge): Pharma’s Next Blockbuster Listing Dec 8–10?

In the volatile pharma IPO arena, where innovation meets investor frenzy, Corona Remedies is stealing the spotlight. As of December 7, 2025, the Corona Remedies IPO GMP clocks in at a robust ₹365, translating to a 34.37% premium over the upper price band—hinting at an explosive listing between December 8–10 on BSE. With India’s healthcare spend projected to hit $372B by 2025, this API manufacturer’s GMP surge screams opportunity for savvy retail players.

Decoding the GMP Fireworks: What’s Fueling Corona’s Momentum?

Corona Remedies, a Chennai-based active pharmaceutical ingredients (API) specialist, isn’t just riding the post-COVID recovery—it’s accelerating. Key drivers:

• Sector Tailwinds: Pharma exports up 12% YoY; Corona’s focus on generics for cardiology and oncology taps into global shortages.
• GMP Trajectory: Steady climb from ₹250 last week, signaling HNI confidence amid stable subscription vibes.
• Fundraise Edge: ₹200 Cr+ issue size earmarked for capex and R&D—classic multibagger blueprint.
• Risk Radar: Regulatory hurdles (FDA nods) could cap upside, but 25% EBITDA margins buffer volatility.

GMP Breakdown: Your Listing Gain Calculator

Investor Verdict: Apply, Flip, or Hold?

At 34% GMP, expect a 25–40% pop on debut, mirroring Sun Pharma’s 2024 SME kin. But diversify—pharma’s P/E at 28x leaves room for corrections. New to IPO GMP trends? Bookmark our live tracker.

CTA: Applied for Corona Remedies? Share your lot size in comments—top insights win a free IPO alert newsletter sub!

Disclaimer: Not financial advice; consult a SEBI-registered advisor. Past GMPs don’t guarantee future gains.

Corona Remedies IPO GMP, Corona Remedies IPO listing Dec 2025, Corona Remedies expected gain 34%, pharma IPO GMP today, Corona Remedies subscription status